News Feed Item

Co-development Terms & Agreements in Pharma, Biotech and Diagnostics

LONDON, Aug. 27, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Co-development Terms & Agreements in Pharma, Biotech and Diagnostics


The Co-development Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading life science companies.

The report provides a detailed understand and analysis of how and why companies enter co-development deals.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual co-development contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of co-development dealmaking and business activities.

The initial chapters of this report provide an orientation of co-development dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in co-development as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of co-development deals. The chapter includes numerous case studies to enable understanding of both pure co-development deals and multicomponent deals where co-development forms a part.

Chapter 4 provides a review of the leading co-development deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, signed by bigbiotech, most active bigbiotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive review of co-development financials for deals announced since 2009, including headline value, upfront, milestone payments and royalty rates by stage of development, providing both benchmark data and access to individual deal financials.

Chapters 6 and 7 provide a comprehensive listing of the top 50 bigpharma and bigbiotech companies with a brief summary followed by a comprehensive listing of co-development deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 8 provides a comprehensive and detailed review of co-development deals signed and announced since 2009 where a contract document is available. The chapter is organized by company A-Z, stage of development at signing, technologyand therapeutic area. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report also includes numerous table and figures that illustrate the trends and activities in co-development dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about co-development as an opportunity to participate in the commercialization of either candidate compounds in development or products already on the market.

Report scope

Co-development Terms and Agreements in Pharma, Biotech and Diagnostics is intended to provide the reader with an in-depth understanding of the co-development trends and structure of deals entered into by leading life science companies worldwide.

Co-development Terms and Agreements in Pharma, Biotech and Diagnostics includes:

Trends in co-development dealmaking in the biopharma industry since 2009
Analysis of co-development deal structure
Case studies of real-life co-development deals
Comprehensive listing of co-development deals since 2009
Access to co-development contract documents
Key financial benchmarks for headline, upfront, milestone and royalty rates
The leading co-development deals by value since 2009
Most active co-development dealmakers since 2009
The leading co-development partnering resources

In Co-development Terms and Agreements in Pharma, Biotech and Diagnostics available deals and contracts are listed by:

Company A-Z
Headline value
Therapeutic area
Technology type

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

The Co-development Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive access to available contract documents for co-development deals. Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How do milestone align with clinical stage development phases?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in co-development dealmaking

2.1. Introduction
2.2. Definition of co-development deals
2.3. Success factors for co-development deals
2.4. When co-development can be useful
2.5. Attributes of co-development deals
2.6. Aligning partners to make the co-development work
2.7. Trends in co-development deals since 2009
2.8. Option to co-develop
2.9. The future of co-development deals

Chapter 3 – Overview of co-development deal structure

3.1. Introduction
3.2. Pure versus multi-component co-development deals
3.3. Pure co-development agreement structure
3.3.1. Example co-development agreements
3.3.1.a. Case study 1: Ambrx – Zhejiang Medicine – June 2013
3.3.1.b. Case study 2: UniQure - Chiesi – July 2013

Chapter 4 – Leading co-development deals

4.1. Introduction
4.2. Top co-development deals by value
4.3. Most active co-development dealmakers
4.4. Bigpharma co-development deal activity

Chapter 5 – Bigpharma co-development deals

5.1. Introduction
5.2. How to use co-development deals
5.3. Company co-development agreement listings

Chapter 6 – Bigbiotech co-development deals

6.1. Introduction
6.2. How to use co-development deals
6.3. Company co-development agreement listings

Chapter 7 – Co-development contract directory 2009-2014

7.1. Introduction
7.2. Company A-Z
7.3. By therapy area
Central Nervous System
Genetic disorders
Hospital care
Orphan disease
Public health
7.4. By stage of development at signing
Phase I
Phase II
Phase III
7.5. By technology area
Biological compounds
Clinical testing
Discovery tools
DNA probes
Drug delivery
Enabling technology
Gene therapy
Industrial chemicals
Natural product
Recombinant DNA
Research services
RNA therapeutics
Small molecules
Software tools


Appendix 1 – Co-development references
Appendix 2 – Resources
Appendix 3 – Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Order Form – Upgrades to subscription access products
Recent report titles from CurrentPartnering
Order Form – Reports

Separate appendix file supplied for:

Appendix 1 – Co-development dealmaking - by financial disclosure
Appendix 2 – Co-development dealmaking - by companies A-Z
Appendix 3 – Co-development dealmaking - by stage of development
Appendix 4 – Co-development dealmaking - by therapeutic target
Appendix 5 – Co-development dealmaking - by technology type


Figure 1: Definition of co-development
Figure 2: Situations where co-development can prove useful
Figure 3: Key components of a co-development deal
Figure 4: Issues in implementing co-development agreements
Figure 5: Trends in co-development deal announcements, 2009-2014
Figure 6: Co-development deals signed at each phase of development, 2009-2013
Figure 7: Co-development agreements – what should a contract include?
Figure 8: Components of the co-development deal structure
Figure 9: Top co-development deals by value since 2009
Figure 10: Most active co-development dealmakers 2009-2014
Figure 11: Bigpharma – top 50 – Co-development deals 2007 to 2013
Figure 12: Bigpharma co-development deal frequency - 2009 to 2014
Figure 13: Online partnering resources
Figure 14: Deal type definitions

Read the full report:
Co-development Terms & Agreements in Pharma, Biotech and Diagnostics


For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Media announced today that @WebRTCSummit Blog, the largest WebRTC resource in the world, has been launched. @WebRTCSummit Blog offers top articles, news stories, and blog posts from the world's well-known experts and guarantees better exposure for its authors than any other publication. @WebRTCSummit Blog can be bookmarked ▸ Here @WebRTCSummit conference site can be bookmarked ▸ Here
You have great SaaS business app ideas. You want to turn your idea quickly into a functional and engaging proof of concept. You need to be able to modify it to meet customers' needs, and you need to deliver a complete and secure SaaS application. How could you achieve all the above and yet avoid unforeseen IT requirements that add unnecessary cost and complexity? You also want your app to be responsive in any device at any time. In his session at 19th Cloud Expo, Mark Allen, General Manager of...
SYS-CON Events announced today that Streamlyzer will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Streamlyzer is a powerful analytics for video streaming service that enables video streaming providers to monitor and analyze QoE (Quality-of-Experience) from end-user devices in real time.
@ThingsExpo has been named the Top 5 Most Influential Internet of Things Brand by Onalytica in the ‘The Internet of Things Landscape 2015: Top 100 Individuals and Brands.' Onalytica analyzed Twitter conversations around the #IoT debate to uncover the most influential brands and individuals driving the conversation. Onalytica captured data from 56,224 users. The PageRank based methodology they use to extract influencers on a particular topic (tweets mentioning #InternetofThings or #IoT in this ...
SYS-CON Events announced today that Super Micro Computer, Inc., a global leader in Embedded and IoT solutions, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 7-9, 2017, at the Javits Center in New York City, NY. Supermicro (NASDAQ: SMCI), the leading innovator in high-performance, high-efficiency server technology, is a premier provider of advanced server Building Block Solutions® for Data Center, Cloud Computing, Enterprise IT, Hadoop/Big Data, HPC and ...
Today every business relies on software to drive the innovation necessary for a competitive edge in the Application Economy. This is why collaboration between development and operations, or DevOps, has become IT’s number one priority. Whether you are in Dev or Ops, understanding how to implement a DevOps strategy can deliver faster development cycles, improved software quality, reduced deployment times and overall better experiences for your customers.
Cloud based infrastructure deployment is becoming more and more appealing to customers, from Fortune 500 companies to SMEs due to its pay-as-you-go model. Enterprise storage vendors are able to reach out to these customers by integrating in cloud based deployments; this needs adaptability and interoperability of the products confirming to cloud standards such as OpenStack, CloudStack, or Azure. As compared to off the shelf commodity storage, enterprise storages by its reliability, high-availabil...
The IoT industry is now at a crossroads, between the fast-paced innovation of technologies and the pending mass adoption by global enterprises. The complexity of combining rapidly evolving technologies and the need to establish practices for market acceleration pose a strong challenge to global enterprises as well as IoT vendors. In his session at @ThingsExpo, Clark Smith, senior product manager for Numerex, will discuss how Numerex, as an experienced, established IoT provider, has embraced a ...
Explosive growth in connected devices. Enormous amounts of data for collection and analysis. Critical use of data for split-second decision making and actionable information. All three are factors in making the Internet of Things a reality. Yet, any one factor would have an IT organization pondering its infrastructure strategy. How should your organization enhance its IT framework to enable an Internet of Things implementation? In his session at @ThingsExpo, James Kirkland, Red Hat's Chief Arch...
@DevOpsSummit has been named the ‘Top DevOps Influencer' by iTrend. iTrend processes millions of conversations, tweets, interactions, news articles, press releases, blog posts - and extract meaning form them and analyzes mobile and desktop software platforms used to communicate, various metadata (such as geo location), and automation tools. In overall placement, @DevOpsSummit ranked as the number one ‘DevOps Influencer' followed by @CloudExpo at third, and @MicroservicesE at 24th.
When people aren’t talking about VMs and containers, they’re talking about serverless architecture. Serverless is about no maintenance. It means you are not worried about low-level infrastructural and operational details. An event-driven serverless platform is a great use case for IoT. In his session at @ThingsExpo, Animesh Singh, an STSM and Lead for IBM Cloud Platform and Infrastructure, will detail how to build a distributed serverless, polyglot, microservices framework using open source tec...
November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Penta Security is a leading vendor for data security solutions, including its encryption solution, D’Amo. By using FPE technology, D’Amo allows for the implementation of encryption technology to sensitive data fields without modification to schema in the database environment. With businesses having their data become increasingly more complicated in their mission-critical applications (such as ERP, CRM, HRM), continued ...
SYS-CON Events announced today that Cloudbric, a leading website security provider, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Cloudbric is an elite full service website protection solution specifically designed for IT novices, entrepreneurs, and small and medium businesses. First launched in 2015, Cloudbric is based on the enterprise level Web Application Firewall by Penta Security Sys...
We are reaching the end of the beginning with WebRTC, and real systems using this technology have begun to appear. One challenge that faces every WebRTC deployment (in some form or another) is identity management. For example, if you have an existing service – possibly built on a variety of different PaaS/SaaS offerings – and you want to add real-time communications you are faced with a challenge relating to user management, authentication, authorization, and validation. Service providers will w...
The Open Connectivity Foundation (OCF), sponsor of the IoTivity open source project, and AllSeen Alliance, which provides the AllJoyn® open source IoT framework, today announced that the two organizations’ boards have approved a merger under the OCF name and bylaws. This merger will advance interoperability between connected devices from both groups, enabling the full operating potential of IoT and representing a significant step towards a connected ecosystem.